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Abstract: Nanotechnology approaches play an important role in developing novel and efficient
carriers for biomedical applications. Peptides are particularly appealing to generate such nanocarriers
because they can be rationally designed to serve as building blocks for self-assembling nanoscale
structures with great potential as therapeutic or diagnostic delivery vehicles. In this review, we describe
peptide-based nanoassemblies and highlight features that make them particularly attractive for the
delivery of nucleic acids to host cells or improve the specificity and sensitivity of probes in diagnostic
imaging. We outline the current state in the design of peptides and peptide-conjugates and the
paradigms of their self-assembly into well-defined nanostructures, as well as the co-assembly of nucleic
acids to form less structured nanoparticles. Various recent examples of engineered peptides and
peptide-conjugates promoting self-assembly and providing the structures with wanted functionalities
are presented. The advantages of peptides are not only their biocompatibility and biodegradability,
but the possibility of sheer limitless combinations and modifications of amino acid residues to induce
the assembly of modular, multiplexed delivery systems. Moreover, functions that nature encoded in
peptides, such as their ability to target molecular recognition sites, can be emulated repeatedly in
nanoassemblies. Finally, we present recent examples where self-assembled peptide-based assemblies
with “smart” activity are used in vivo. Gene delivery and diagnostic imaging in mouse tumor models
exemplify the great potential of peptide nanoassemblies for future clinical applications.
Keywords: peptide nanoassemblies; micelles; nanovesicles; nanotubes; nanofibrils; nanoprobes;
peptide conjugates; cell penetrating peptides; non-viral gene delivery; diagnostic imaging
1. Introduction
Peptides have several advantages that make them highly attractive building blocks for tailoring
nanoassemblies to biomedical applications [1–3]. In this regard, the side chain properties of amino acids,
including hydrophilicity, hydrophobicity, charge, and polarity, allow for accomplishing certain functions
in biological systems [4]. In addition, a family of membrane active peptides are inherently capable
of conferring targeting or membrane translocating properties upon different bioactive cargoes [2,5].
Playing a major role as modulator of many cellular functions [6], peptides have the potential to fulfil
critical prerequisites for successful gene delivery and diagnostic systems [2,5]. There is increasing
evidence for the incorporation of peptides as recognition/targeting moieties, gene delivery, and diagnosis
modules in a broad range of biomedical applications [7].
Self-assembly of peptides into supramolecular structures takes place when adequate non-covalent
interactions between peptide chains occur. Several other factors, including concentration, buffer
composition (pH, ionic strength), and temperature also influence the self-assembly process [8].
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Significant progress has been made in the field of self-assembly and a large variety of peptide-based
supramolecular structures with customized properties were developed [4,9]. Consequently, the ease of
“bottom-up” fabrication through rational design of amino acid sequences offers infinite smart nanoscale
architectures, with sizes ranging from few to hundreds of nanometers [10].
In this review, we introduce different peptide-based nanoassemblies, such as micelles, vesicles,
nanofibers, nanotubes, and nanoparticles, with a multitude of distinct physicochemical properties.
We highlight the principles that lead to the intended supramolecular structure and how they are
tailored to carry out specific functions. Due to the versatility of peptides and the vast diversity of the
ensuing nanoassemblies, we chose to focus on two applications that are of utmost medical relevance,
namely gene delivery and diagnosis. The prospect of combining the advantageous properties of
peptides with those of dimensions in the nanoscale regime make peptide-based nanomaterials prime
candidates for many biomedical applications, in particular as vehicles for carrying therapeutic agents
like nucleic acids or detectable probes to specific sites in the body [11]. Therefore, we look into the
potential of peptide-based nanoassemblies as delivery vector in gene therapy because of their ability to
bind/conjugate or entrap/condense DNA or RNA, and in diagnostic imaging, because of their targeting
propensity [12].
In recent years, gene insertion and interference therapies using viral vectors have made a ground
breaking impact in the treatment of rare inherited diseases, neurological disorders, cardiac diseases,
and cancer [13]. Several disadvantages of viral-vectors, such as high toxicity and immunogenicity,
limitation in size of transgenic DNA, and high manufacturing cost, have triggered the rapid expansion of
non-viral delivery systems, including peptide-based vectors [14]. Thus, we will discuss peptide-based
assemblies with regard to the advantages they offer for increasing the efficacy of gene delivery in vivo,
such as targeting and overcoming different kinds of biological barriers like plasma and endosomal
membranes [14].
The sensitive and accurate detection of specific targets in the body, in particular molecular
markers of diseases in organs and tissues, is key to diagnostic imaging. Corresponding nanoprobes
that enable a rapid and accurate diagnosis are of crucial importance for effective therapy and
the prevention of disease progression to ultimately incurable stages [15]. Clinical and preclinical
applications of wide range of imaging nanoprobes, emphasize the potential offered by combining
modern nanotechnology and molecular imaging science for early-stage diagnosis [16–18]. In recent
years, peptide-based nanoassemblies have made considerable headway towards providing novel
advanced molecular imaging nanoprobes with great accuracy and precision [19]. In modern imaging,
peptide-based nanoprobes aimed at improving in vitro and in vivo performance of water-soluble
molecular probes [19,20]. Conclusively, we describe some recent in vivo examples of diagnostic
imaging and gene delivery that reveal the great potential of peptide-based nanoassemblies, for future
clinical applications.
2. Peptide-Based Supramolecular Nanoassemblies
Peptide self-assembly has emerged as a promising research field in nanomedicines, due to the many
advantages associated with multifunctional well-defined peptide-based nanoassemblies [21–25]. Common
amphiphilic peptides and peptide-conjugates yielding supramolecular assemblies for biomedical
applications include linear, ionic complementary, long-chain alkylated, and lipo-peptides [26].
Compared to individual peptides, peptide self-assemblies offer several unique features, like multivalent
binding, dynamic control of cargo interactions, responsiveness to environmental and cellular cues,
and long circulation times [27]. Various peptide-based supramolecular architectures like micelles,
vesicles, nanofibers, nanotubes, and nanoparticles can be generated via a rational design of the
molecular building blocks (Figure 1) [28]. As polar and nonpolar regions coexist in amphiphilic
peptides, self-assembly can be readily accomplished through microphase separation [29,30].
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biomedicine, are closed monolayers consisting of a hydrophobic inner core surrounded by a 
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spherical structures with narrow size distribution occurs above a critical micellar concentration 
(CMC) and can be governed by temperature [35–37]. 
For gene delivery applications, peptide-based micelles offer several advantages like high 
stability, high therapeutic potency due to efficient gene loading, and small size conducive to deep 
tumor penetration and cellular uptake [38]. Notably, formation of cationic micellar nanoassemblies 
increases the local positive charge density in solution, supporting an effective DNA condensation 
[38]. For example, cationic peptide dendrimers with side arm lipid conjugates that were able to self-
assemble into micelles and condense siRNA, were introduced as a versatile platform for effective 
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2.1. icelles
Peptide-based micelles, probably the most prominent self-assembly nanostructures in biomedicine,
are closed monolayers consisting of a hydrophobic inner core surrounded by a hydrophilic outer
shell (Figure 1). Direct dissolution and solvent switch are the two most common methods for micelle
preparation. The spontaneous formation of these well-ordered supramolecular spherical structures
with narrow size distribution occurs above a critical micellar concentration (CMC) and can be governed
by temperature [35–37].
For gene delivery applications, peptide-based micelles offer several advantages like high stability,
high therapeutic potency due to efficient gene loading, and small size conducive to deep tumor
penetration and cellular uptake [38]. Notably, formation of cationic micellar nanoasse blies
increases the local positive charge density in solution, supporting an effective DNA condensation [38].
For example, cationic peptide dendrimers with side arm lipid conjugates that were able to self-assemble
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into micelles and condense siRNA, were introduced as a versatile platform for effective nucleic
acid delivery [39]. The peptide-based micelles were non-cytotoxic at various concentrations and
demonstrated superior delivery efficiency over common transfection agents, like Lipofectamine 2000
or Lipofectin®. In another example, a rationally designed amphiphilic peptide that self-assembled
into multicompartment micelles (MCMs) was able to efficiently entrap single- and double-stranded
DNA up to 100 nucleotides in length (Figure 2A,B) [40]. These purely peptidic, nanosized MCMs
demonstrated rapid and efficient uptake by cells (Figure 2C).
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ationic peptide-based icelles are not only able to condense nucleic acids effectively, but they
can be tailored to target specific cells and to facilitate cellular uptake, endosomal escape, and transport
to the nucleus [38]. In this context, a multifunctional (CR8GPLGVH5-Pal) dipeptide comprising
a cell-pe etrating moiety (R8), a matrix metalloproteinase-2 (MMP-2) specific sequence (GPLGV),
pH-responsive residues (H5), and a hydrophobic moiety (pal itic acid, Pal) self-assembled into micelles
and condensed plasmid DNA (pDNA), resulting in an efficient vector for gene delivery [41]. Another
cationic amphiphilic peptide, R3V6, that self-assembled into micelles showed remarkable potential for
the com ined delivery of siRNA and carmustine (an anti-cancer drug) to C6 glioblastoma cells [42].
Carmustine was efficiently entrapped into the hydrophobic core of the micelles, whereas the siRNA
formed a stable complex with the positively charged amino acid residues of the ydrophilic shell.
Maj r efforts in the field of gene therapy were aimed at achieving enhanced stability, prolonged
circulati n time and controlled e e release of the nanovectors [38]. Amphiphilic cationic A12H5Kn
(n = 10 or 15) pepti e assembled micelles with hydrophobic alanine residues, forming the core, cationic
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lysine residues supporting the interaction with charged DNA and histidine residues promoting the
endosomal escape of the micelles [43]. Such A12H5Kn micelles demonstrated strong DNA-binding
ability and efficient protection of entrapped DNA. Consequently, HepG2 and 4T1 cell lines showed
significantly higher expression of a reporter gene delivered by micelles than cells transfected with
corresponding polyethilenimine/DNA complexes.
Self-assembled peptide-based micelles can also be used for disease diagnosis, in particular
in cancer. Self-assembled micelles based on C-3, an amphiphilic RVRRFFF peptide coupled to a
nitrobenzoxadiazole fluorophore (NBD) were developed for recognizing cancer cells with high furin
expression since RVRR is a cleavage site for furin [44]. When taken up by living cells, C-3 micelles
allowed the successful detection of furin by the dissociation of micelles accompanied by an increase in
fluorescence. Thus, as furin was reported to be abnormally expressed in various cancers, C-3 micelles
might prove valuable tools for the early diagnosis of certain cancers.
Notably, peptide-based micelles can simultaneously exhibit diagnostic and therapeutic
properties [45]. For example, amphiphilic peptide-based conjugates made up of a fibrin-binding
peptide, CREKA, or a fluorescently labeled CREKA conjugate (Cy7-CREKA) like a cationic head group,
a PEG2000 spacer, and a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) hydrophobic tail,
formed micelles that served for theranostic systems in cancer and atherosclerosis (Figure 3A) [46,47].
When Cy7-CREKA micelles were injected intravenously into an intracranial GL261 glioma mouse model
(Figure 3B), the peptide-based micelles accumulated at the tumor site within 1 h, post injection [46].
By day 7, the majority of the micelles were cleared and the organs showed no signs of cytotoxicity or
tissue damage, as determined by histological evaluation. The active binding of Cy-7 CREKA to fibrin
within the glioblastoma blood vessels confirmed the tumor-homing property of these micelles.
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pentaacetic acid (gadolinium salt) (18:0 PE DTPA(Gd)) to form gadolinium containing a peptide-based
cancer detection, by an improved contrast in the magnetic resonance imaging (MRI) [49].
Peptide-based micelles were engineered to respond to various internal or external stimuli, ultimately
yielding functional “smart” nanostructures [3]. The major goals of stimulus-responsiveness in micelles
tuned for gene delivery are to achieve enhanced or controlled gene release, improved cellular uptake,
and control over the intracellular fate of nucleic acids [50,51]. For example, micelles assembled from a
pH-responsive chimeric peptide, (Fmoc)2KH7-TAT, in the presence of pGL-3 reporter plasmid DNA
(pDNA) and doxorubicin (DOX) were used to transfect 293T and HeLa cell lines [52]. Once enodcytosed
by cells, the imidazole group of the histidine residues got protonated in the acidic environment of
the endolysosomal compartment, resulting in swelling of the micelles. Besides facilitating endosomal
escape, the loss of micelle compactness caused a cumulative fast release of DOX and pDNA, which
effectively inhibited cell growth in vitro and significantly restrained tumor growth in vivo.
2.2. Vesicles
Vesicles are spherical, bilayer-delimited hollow assemblies made from one or more types of
amphiphilic molecules (Figure 1) [28]. Hydrophilic domains are exposed to the inner and outer aqueous
environments, whereas hydrophobic residues pack together between hydrophilic interfaces [53].
Accordingly, vesicles are capable of entrapping hydrophilic molecules in the interior aqueous phase
and hydrophobic molecules in the hydrophobic parts of the bilayer [54]. The vesicle size can be tuned
by adjusting the composition and chain length of the building blocks [3,55].
Self-assembly of pure amphiphilic oligopeptides [56] and diblock copolypeptides [57,58] resulted
in vesicle formation in aqueous solution. The hydrophobicity of the peptide’s tail largely determines
whether the peptides assemble into vesicles or nanotubes (see below). Furthermore, surfactant-like
peptides with a hydrophilic head domain that consisted of aspartic acid residues, and a hydrophobic
tail made of 4−10 glycine residues were shown to self-assemble into vesicles of about 30–50 nm in
diameter [59,60].
Due to the intrinsic chemical and biological properties of peptides, peptide-based nanovesicles
offer several advantages over liposomes, such as better membrane fluidity, targeting, biocompatibility,
and stability [61,62]. For in vivo delivery of DNA, peptide-mediated targeting and also the protection
of the cargo against threatening extracellular factors, are of particular significance. Maintaining
DNA stability and prolonging its circulation time, promote an improved organ distribution [63,64].
Self-assembled peptide vesicles (SPVs) were modified by a wide range of chemical functionalizations,
including conjugating other peptides or bioactive molecules to the outer surface, or by encapsulating
specific cargoes in the aqueous cavity or hydrophobic domain of the membrane [65,66]. A good
representative of this kind of multifunctional SPV platform is based on the epidermal growth factor
receptor (EGFR) binding peptide GE11 conjugated to glycidyl hexadecyl dimethylammonium chloride
(GHDC) (Figure 4A) [67].
When cholesterol (Chol) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was added
to the self-assembly of GE11-GHDC, EGFR-targeting SPVs with a stabilizing lipid bilayer structure
were obtained (Figure 4B-a). Further modifications of the peptide platform were achieved by
including hydrophobic (e.g., anticancer drugs, quantum dots (QD), Figure 4B-b) or water-soluble
cargoes (fluorescent dyes, anticancer drugs, nucleic acids, Figure 4B-c). For example, cationic SPVs
(GE11-GHDC/ HQCMC/Chol) with a high positive zeta potential were prepared for the delivery of
genes or siRNAs. The inclusion of fluorescent compounds for easy localization further extends the
functionalities of SPVs and turns them into theranostic platforms. GE11-GHDC-based vesicles that
were functionalized, correspondingly demonstrated EGFR targeting, gene transfer, and high potency
for tumor growth suppression in vivo.
Furthermore, as with micelles, peptide building blocks provide the possibility of designing vesicles
that are highly sensitive to local environmental conditions (e.g., pH, redox potential, enzymes) or
external stimuli (light, magnetic field, ultrasound) [57,68]. For example, cationic vesicles derived
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from a polypeptide with a hydrophobic poly(l-glutamate) (PLG) backbone and a pH-responsive
hydrophilic poly(2-aminoethyl methacrylate hydrochloride) (PAMA) side chain loaded with Doxorubicin
hydrochloride (DOX·HCl) were able to release the cargo upon a change of pH, due to protonation of
PAMA side chains [69]. The interaction of cationic PLG-g-PAMA vesicles with DNA suggested that
these vesicles might prove useful for the codelivery of therapeutic drugs and genes.
Poly(l-lysine hydrochloride)(PLL) and poly(gamma-benzyl-d7-l-glutamate) copolypeptides were
also shown to form pH- and temperature-sensitive vesicles, when combined with pDNA [70]. In this
case, the pDNA was partially condensed on the PLL phase and partially encapsulated inside the
vesicle, resulting in an enhanced protection.
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2.3. Nanofibers
Nanofibers are cylindrical structures with a length of up to microns and a width typically between
5 to 20 nm (Figure 1). The high surface-to-volume ratio provides nanofibers with a large capacity
for loading various bioactive molecules, including nucleic acids [27,30]. Amyloid peptides, ionic
self-complementary peptides, collagen-like triple helical peptides, and amphiphilic peptides are able
to self-assemble into nanofibers [71].
Secondary structure and side-chain interactions are widely perceived to play a crucial role in the
self-assembly of nanofibers. Accordingly, while considering the hydrophobic–hydrophilic balance,
amino acid sequences can be tailored to promote nanofiber formation [29]. For example, nanofiber
self-assembly based on short amphiphilic peptides primarily relies on highly hydrophobic amino
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acids (Ile or I) and their propensity for β-sheet structuring [72]. The peptide-based nanofibers (PNFs)
adopt a β-sheet secondary structure to elongate into ordered nanofibers [73]. Besides sheet formation,
the collapse of hydrophobic alkyl chains also promotes nanofiber assembly [74]. Accordingly, PNFs for
gene delivery are composed of three main domains—(1) a hydrophobic tail, predominantly an alkyl
chain, (2) a β-sheet forming peptide sequence capable of intermolecular hydrogen bonding, and (3)
a hydrophilic head made out of basic amino acids that are positively charged under physiological
conditions [22]. Provided the hydrophilic head is located at the exterior of the nanofibers, bioactive
molecules can be entrapped within the network, during the self-assembly process [29]. Hence,
PNF self-assembly and functionality profoundly depend on all three domains [75]. PNFs are promising
tools for gene delivery as they can be engineered to form a platform of positively charged amino
acids that electrostatically interact with nucleic acids. For example, PNFs as a non-viral vector system
for siRNA delivery demonstrated effective knockdown of a targeted protein (BCL2) expression and
induced apoptosis in vitro [76]. Moreover, an increased residence time as well as biological activity of
siRNA was shown after administration of the PNF/siRNA complexes to the rat brain.
Recently, an amphiphilic peptide NH2-KIWFQNR-COOH with cationic residues at both termini to
condense DNA was reported to promote the elongation of nanofibers by β-sheet pairing and β-stacking
(Figure 5A–C) [77]. Fibril formation involved double-stranded DNA as a template inducing peptide
fibrillization (Figure 5D). The resulting nanofibers were likely composed of DNA cores surrounded by
a peptide shell. Atomic force microscopy revealed the formation of interconnected nanofiber networks
for both KIW7/200bpDNA (Figure 5E) and KIW7/pDNA (Figure 5F), with nanofibers of width 20 nm.
These results suggest that peptidic nanofibers through noncovalent strategies have a remarkable
potential for DNA delivery.
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PNF-AuNCs were efficiently used for fluorescence imaging of HeLa cells, whereby the RGD 
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nanostructures co-assembled from different peptide amphiphiles (PA) containing a β-sheet forming 
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Figure 5. Schematic representation of the structural model proposed for complexation between KIW7
and DNA. (A) Fibrillary scaffold with a DNA core (orange ribbons) templating the growth of a peptide
shell. (B) β-sheet paring between adjacent KIW7 chains in the fibers. (C) Supramolecular stacks
formed by π-π interactions between phenylalanine and tryptophan. (D) Illustration of nucleation
and growth of peptiplexes through liquid–liquid phase separation. AFM topography from KIW7
peptide complexed (E) with 200 bp DNA, and (F) with pDNA. Adapted and modified from [77],
with permission. Copyright: 2020 Royal Society of Chemistry.
Obviously, PNFs lend themselves to theranostic applications and have been widely employed as
advanced materials for imaging [78]. Accordingly, gold nanoclusters (AuNCs) were introduced into
self-assembled PNFs to enhance their luminescence efficiency. For example, in the presence of HAuCl4,
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the amphiphilic peptide (RGDAEAKAEAKCCYYCCAEAKAEAKRGD) self-assembled into a nanofiber
scaffold for AuNCs where the luminescence of AuNCs was enhanced nearly 70-fold [79]. PNF-AuNCs
were efficiently used for fluorescence imaging of HeLa cells, whereby the RGD recognition motif at
both ends of the peptide allowed specific targeting. Similarly, fibrillar nanostructures co-assembled
from different peptide amphiphiles (PA) containing a β-sheet forming hydrophobic block and a
linker peptide conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) were used
for improving contrast in MRI [80]. Large amounts of Gd3+ could be chelated to the fiber surface,
suggesting that PNFs that can be potentially used as nanoprobes in magnetic resonance imaging (MRI).
2.4. Nanotubes
Peptide nanotubes (PNTs) are three-dimensional, highly organized systems that maintain a
well-defined hollow cylindrical shape by molecular interactions of the amphiphilic building blocks
(Figure 1) [81]. PNTs provide numerous possibilities for functionalization, for example at the head
group of the peptide amphiphiles, and thus these versatile structures are candidates for a broad
range of applications [82]. Considering that the hydrophobic alkyl chains orient towards the core and
the amino acid residues to the outer surfaces, the functional groups appear on the outer surfaces of
PNTs [83]. However, PNTs represent relatively a new concept in nanomedicine and therefore only few
examples were reported [84].
PNT formation is mainly governed by the peptide sequence and the ensuing intermolecular
hydrogen bonds between amino acid residues [83]. PNT formation from amphiphilic peptide-derived
monomers naturally progresses according to well-established phase diagrams for nanotube
assemblies [85]. Notably, the solution pH and hydrophobicity of peptide monomers are the prominent
factors in determining PNT formation and dimensions [74,86].
Organic nanotubes based on the rational design of cyclic polypeptides were first reported by
Ghadiri and coworkers [87,88]. These cyclic peptides spontaneously self-assemble into long channel
structures via extension of hydrogen-bonded stacking interactions and, when exposing suitable
hydrophobic residues on the surface, wrap the lipid bilayer around themselves [88]. Moreover,
the transmembrane channels from self-assembling PNTs were suggested to have potential for gene
delivery into living cells [88]. Similarly, cyclic cyclo-(d-Trp-Tyr) formed nanotubular assemblies in
the presence of pDNA, mediating an enhanced in vitro and in vivo duodenal permeability for the
pDNA [89]. These results highlighted the potential application of this oral gene delivery system for the
genetic treatment of diseases associated with duodenum, stomach, liver, and kidney.
Surfactant-like peptides can also self-assemble into nanotubes with the main driving force in
assembly being the formation of a polar interface that sequesters the hydrophobic tail from water
contact [90]. The formation of well-defined hierarchical super-secondary structures is then induced by
specific side chain hydrogen bonding interactions amongβ-sheets [91]. For example, a super-secondary
structural template based on well-defined hydrogen bonds was developed via rational design and
self-assembly of short amphiphilic Ac-I3XGK-NH2 (X = Q, S, and N) peptides [91]. The combination of
hydrophobic adhesion and polar zipper formation between neighboring β-sheets rather than between
β-strands within a sheet, intermeshed the β-sheets into stable, wide and flat ribbons. In another
example, different surfactant-like peptides with a cationic head group (one or two Lys and His) and a
hydrophobic tail of six Ala, Val, or Leu residues self-assembled when the pH values were higher than
the peptide’s isoelectric point [92]. Depending on the assembly conditions and corresponding charge
properties of the amino acids, nanotubes were formed. Due to their cationic nature, PNTs can bind
negatively charged DNA or siRNA, making them suitable for gene delivery applications.
Furthermore, peptide–polymer or peptide-lipid hybrid nanotubes have been extensively studied
as promising nontoxic nanostructures for biomedical applications [93,94]. They commonly consist of a
peptidic core and a covalently attached polymeric or lipidic coating. Their biomedical applications
including gene delivery were already reviewed [95].
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2.5. Nanoparticles
The formation of stable and compact nucleic acid/peptide nanoparticles (NPs), also called
peptiplexes is induced by electrostatic interactions between positively charged peptides and the
negatively charged phosphate backbone of nucleic acids (Figure 1). Over the past two decades, these
peptide-DNA complexes emerged as efficient gene carrier systems [96,97]. Notably, peptide-based
transfection agents have several advantages over well-established polyplexes (cationic polymer-DNA
complexes) or lipoplexes (cationic lipid-DNA complexes) including biocompatibility and easy synthesis
process on a large scale. As compared to their lipid counterparts, peptides can be more stable with
regard to oxidation, but especially benefit from countless tunability possibilities [98–100]. Peptiplex
formation occurs when 90% negative charge of the DNA phosphate groups are neutralized by transition
into the ordered phase [101]. In order to condense pDNA into NPs, a minimum of six to eight positive
charges per peptide is required, although 13 or more positive charges are often needed for obtaining
stable peptiplexes [101,102].
Various cationic peptides comprising different combinations of lysine, arginine and histidine
residues have been exploited for nucleic acid condensation. Owing to the presence of protonable
amine groups on lysine residues, lysine-rich peptides are known to effectively condense nucleic
acids with a strong dependency on genetic payload concentration [103]. For example, a branched
amphiphilic peptide with oligo lysine segment was able to condense GFP encoding pDNA into
nanosized peptiplexes due to the strong electrostatic interactions at low peptide to pDNA ratio [104].
The compacted peptiplexes (Figure 6A), transfected HeLa cells at a higher rate than corresponding
complexes with Lipofectin, a lipid-based transfection reagent (Figure 6B).
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Like ise, nanoparticles built by a t o-step self-asse bly of globular peptide dendri ers ith
lysine endgroups and poly(l-leucine) carrying one glutamic acid residue, exhibited potential for
gene therapy applications [105,106]. Cationic Cys-Trp-Lysn peptides with 3 to 36 lysine residues
were developed to systematically investigate the optimal lysine chain length for DNA condensation
and transfection efficiency [107]. Peptides containing 13 or more lysines were able to strongly
bind DNA and form small NPs (from 50 to 200 nm), while peptides with eight or fewer lysines
formed large particles (0.7–3 µm) due to insufficient positive charges, resulting in weak DNA
condensation. Interestingly, compared to Cys-Trp-Lys19/DNA peptiplexes, Cys-Trp-Lys18/DNA
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peptiplexes demonstrated a 1000-fold increase in transfection efficiency. However, lysine-rich peptides
suffer from relatively high cytotoxicity but also from low transfection efficiency, especially if high
molecular weight peptides are involved [108].
Arginine-rich peptides are similarly conducive to tight gene condensation, and due to their ability
to promote cell penetration, they are effective delivery systems [109,110]. RALA, an amphipathic,
cell penetrating peptide with seven arginines in its backbone, formed peptiplexes with siRNA as well
as pDNA, which were used as delivery platform in vitro and in vivo (Figure 7) [111–114].Molecules 2020, 25, x FOR PEER REVIEW 11 of 37 
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By the same token, hydrophilic histidine residues due to their positive charge at physiological pH,
bind and condense nucleic acids in aqueous solution [115]. Moreover, protonation of its imidazole
ring at low pH, functions as an effective mediator of gene delivery by promoting endosomal escape
and gene release. Accordingly, short linear peptides containing multiple histidines were reported
to increase DNA transfection efficiency [116], which could be further improved by using branched
peptides where histidines are incorporated at higher density [117].
Interestingly, the combination of arginine and histidine was found to boost the cell penetration
ability of nanoparticles and, thus, improve transfection efficacy [118]. A cationic amphiphilic K12H6V8
peptide comprising three blocks, a lysine block for DNA binding, a histidine block for endolysosomal
release, a valine block as the hydrophobic component, formed peptiplexes with gene delivery
properties [119]. Further modification of the cationic peptide with LHRH ligand (KHV-LHRH) resulted
in significantly higher and more specific gene expression than K12H6V8 in MCF-7 cancer cells.
Furthermore, amphiphilic F6G6(rR)3R2 peptide consisting of a hydrophobic amino acid sequence,
a linking hexaglycine and a hydrophilic cell-penetrating sequence formed NPs that when combined
with thermally activated delayed fluorescence (TADF) molecules, served for fluorescence imaging
in the oxygenic environment of living cells (Figure 8) [120]. The well-dispersed NPs protected
the encapsulated TADF molecules from oxidation and the cell-penetrating properties conveyed by
arginine residues enabled the transport of the entrapped hydrophobic fluorophores across the cell
membrane barrier.
Similarly, by using porphyrin as photoactive dye, photothermal NPs based on the self-assembly of
peptide–porphyrin conjugates (TPP-G-FF) for simultaneous photo acoustic imaging and photothermal
therapy were developed [121]. The FF, deduced from Alzheimer’s β-amyloid polypeptide was the
core self-assembling motif driving the formation of well-defined peptide porphyrin-photothermal
nanodots (PPP-NDs). Owing to strong π-stacking in the spherical PPP-NDs, the light-to-heat energy
conversion was highly efficient.
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(inset) of TADF NPs prepared at 25 µg/mL of (a) 4CzIPN, (b) NAI-DPAC, and (c) BTZ-DMAC. Scale
bars = 100 nm. Reproduced from [120], with permission. Copyright: 2018 American Chemical Society.
3. In Vivo Applications of Peptide-Based Nanoassemblies for Nucleic Acid Delivery
An ideal nucleic acid delivery system should have the following general features besides
application specific functionalities: (1) effectively compact and protect the genetic payload in vectors
within 10–300 nm in size, (2) maintain stability from the site of administration to the site of action,
(3) readily reach the target cell/tissue and enter it, and (4) in case of endocytic uptake, disrupt the
endosomal membrane and release the nucleic acid such that it has access to the site of action [122,123].
What mostly hampers in vivo application of non-viral vectors is that the desired responses observed
in vitro do not translate well in vivo, and that the delivery systems often prove to be toxic [33].
Peptide-based vectors offer the prospect of overcoming delivery barriers, including the host’s immune
response, and can be tailored to have low cytotoxicity [15].
As described above, individual, positively charged amino acids, like lysine, histidine, and arginine
or their combination in short peptide sequences can strongly influence the performance of non-viral
gene vectors, due to their chemical characteristics. Thus, there are numerous peptides incorporated as
functional motifs into non-viral gene delivery systems that are suited for in vivo application. However,
the number of purely peptidic nanoassemblies for nucleic acid delivery in vivo is significantly lower.
So far, the only pure peptidic nanoassemblies studied in vivo are peptiplexes [32]. Notably, peptiplexes
intended for in vivo applications are often further modified by the covalent attachment of poly(ethylene
glycol) (PEG) to reduce in vivo serum protein adsorption, increase stability of the conjugates in blood,
and prolong the half-life of the genetic payload through reduced renal clearance [123,124]. With regard
to nucleic acid delivery systems, addition of PEG can also have beneficial effects on nucleic acids by
increasing their stability against nucleases [124–126].
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In this section, we summarize recent developments related to the in vivo application of
nanoassemblies for nucleic acid delivery that are exclusively based on peptides.
3.1. Peptidic Nanoassemblies with Cell-Penetrating Properties
In gene therapy, the plasma membrane represents a major hurdle for the delivery of nucleic
acids into the cell [14]. Cationic or amphiphilic cell penetrating peptides (CPPs) are able to mediate
nucleic acid translocation through the cell membrane, without cytotoxic effects [127]. Consequently,
CPPs have become a topic of interest in non-viral gene delivery and their application has dramatically
increased [128,129]. Biodegradable Poly-l-lysine (PLL) derivatives were one of the first cationic cell
penetrating polypeptides found to readily penetrate the cell membrane via a receptor-independent
mechanism [130]. Upon interacting with nucleic acids, PLL condensed into nanoassemblies with
tunable charges and molecular masses varying from a few thousand to nearly one million Daltons [32].
An in vitro and in vivo comparison of PLL/pDNA peptiplexes and SuperFect® polyplexes suggested
that peptiplexes have improved transfection efficacy and are a safer non-viral delivery system [131].
In another study, incorporation of star-shaped PLL/pDNA peptiplexes into a collagen scaffold, resulted
in successful in vivo transfection of autologous host cells, indicating the potential of this system in tissue
engineering (Figure 9) [132]. Star-shaped PLL/pDNA peptiplexes demonstrated a 2-fold increase in
reporter transgene expression, compared to the widely used vector polyethylenimine, a 44-fold increase
compared to a 32-armed star-PLL and a 130-fold increase compared to its linear analogue. In addition,
PEGylated PLL minimized systemic non-specific interactions and consequently improved the delivery
efficiency and safety profile of gene vectors [133]. PEGylated PLL/siRNA peptiplexes were applied as
anti-angiogenesis gene therapy in hepatocellular carcinoma and showed high anti-tumor efficacy [134].
Different PEGylated PLL/pDNA polyplexes were introduced as a promising candidate for lung gene
therapy directed at airway epithelial cells, after their administration into the airway [133].
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lysine, are firmly supported by numerous studies [136,137]. For example, R15 peptiplexes delivering
a β-galactosidase gene into mouse dermal tissue resulted in high levels of gene expression [138].
In another study, targeted gene-therapeutic peptiplexes comprising a redox-sensitive poly(oligo-L-
arginine) (rsPOLA)/pDNA significantly reduced atherosclerotic inflammation in mice (Figure 10) [139].
The reductive environment inside the cells lead to rsPOLA disulfide bond disruption and release of
the gene (Figure 10B). Lesion size measured by computer-associated morphometry revealed a 30%
decrease in the mean lesion area of the aortic sinus, for groups treated with peptiplexes, compared to the
control groups (Figure 10D,E). Several other in vivo studies validated reducible poly(oligo-D-arginine)
(rPOA)/pDNA complexes as an efficient non-viral gene carrier in the treatment of hypoxic–ischemic
brain injury, spinal cord tumors, and in ischemic heart and lung diseases [140–143].
Importantly, peptide dendrimers, highly branched and star-shaped macromolecules with great
molecular uniformity and monodispersity, are well-studied examples for non-viral gene delivery in vivo,
based on their cell penetrating properties, as well as their potential to facilitate intracellular delivery of
the genetic payload [144,145]. For example, arginine functionalized peptide dendrimers condensing
pDNA resulted in a 6-fold higher transfection efficiency than polyetherimide/DNA complexes in breast
tumor models, and were well-tolerated [146]. Comparison of a series of 14 cationic peptides including
linear peptides, lipopeptides, and peptide dendrimers, revealed that LTP, an arginine-rich cationic
peptide dendrimer, exhibited the greatest activity in decreasing the allergic lung inflammation in
mice that were injected with LTP/siRNA nanocomplexes [147]. Likewise, comparison of a linear and
branched structure of a CPP comprising modified bioreducible nona-arginine (B-mR9) (Figure 11A)
revealed that branched mR9/siRNA peptiplexes were superior with regard to serum stability, tumor
accumulation, selective gene release and gene-silencing [148]. Correspondingly, the in vivo biodistribution
study demonstrated that naked dye was distributed throughout the body within 1 h and was mostly
cleared after 24 h while dye-labeled B-mR9/siRNA peptiplexes accumulated well at the tumor sites
where they were still detectable even after 48 h (Figure 11B). Similar advantages were associated with
PEG-cleavable dendrigraft PLL/siRNA polyplexes, as evidenced by a pronounced inhibition of tumor
growth in vivo [149].
Interestingly, the combination of arginine and lysine residues conferred an enhanced cell
penetration ability upon the peptiplexes, resulting in a higher transfection efficiency [128,136].
The in vivo gene transfer study of tissue-specific (KR)4 peptide derived (i.e., GM102 and GM202)
peptiplexes showed a remarkable resistance of the NPs against plasma-induced disintegration and,
thus, an enhanced transfection efficiency [136]. Another cell-penetrating GGG(ARKKAAKA)4 peptide
containing arginine and lysine residues also formed complexes with pDNA or with siRNA [150].
The siRNA peptiplexes were efficiently delivered across the plasma membrane of ocular tissue in vitro
and in vivo [150].
In line with the fact that that CPP complexation with pDNA results in remarkable improvement
of transfection efficiency [127], intramuscular or intradermal injection of stearylated cell penetrating
transportan 10 (TP10)/pDNA peptiplexes resulted in efficient gene transfection, without any associated
toxicity or immunogenicity [151]. Subsequently, by introducing trifluoromethylquinoline and fatty
acid modifications to TP10, a novel CPP, PepFect6 was developed to facilitate endosomal release.
While PF6/luc-siRNA nanoplex-treated mice displayed reduced expression of targeted luciferase for
2 weeks (reaching 75% silencing at day 5), naked luc-siRNA was unable to induce an RNAi response.
PF6/siRNA nanoplexes promoted strong siRNA-mediated gene knockdown in liver, after tail-vein and
hydrodynamic injection [152].
The amphipathic cell-penetrating RICK peptide, a retro inverso form of CADY-K, formed
complexes with siRNAs that entered cells via direct translocation [153]. In vivo evaluation of a
PEGylated formulation of RICK/siRNA targeting cell cycle proteins demonstrated highest knock-down
efficiency, highlighting its potential in cancer gene therapy.
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cells by means of CPP-mediated permeabilization. The branched structures of B-mR9 were then 
cleaved by the reductive conditions of the cytoplasm. Finally, pDNA or siRNA was released into the 
nucleus or cytoplasm, respectively. (B) Naked dye and B-mR9/siVEGF polyplexes were intravenously 
injected into NCI-H460 tumor-bearing mice and the biodistribution was observed over 48 h. Adapted 
and modified from [148], with permission. Copyright: 2017 Elsevier. 
Basic amphiphilic ppTG1 and ppTG20 peptides used for pDNA delivery showed membrane-
destabilizing activities that correlated with the peptides’ tendency to predominantly be in an α-helical 
conformation [154]. Compared to control peptides, the peptiplexes showed a higher gene transfer 
efficiency in the lung, 24 h after tail-vein injection. Similarly, a cationic helical cell-penetrating 
PVBLG-8, in combination with anionic random-coiled poly(L-glutamic acid) (PLG) polypeptides was 
applied for siRNA delivery [155]. PLG was incorporated in the peptide structure to promote and 
stabilize the polypeptide/siRNA nanocomplexes. Due to the high α-helix-dependent membrane 
penetration properties of PVBLG-8 and the stability of the complex, these peptiplexes overcame 
multiple biological barriers and revealed unique tumor targeting, tumor penetration, and selective 
internalization features in xenograft-bearing mice. Likewise, an essential role of helical secondary 
structure for plasma and endosomal membrane penetration in promoting cellular uptake and siRNA 
release was observed with cationic PPABLG polypeptide (Figure 12) [156]. Accordingly, systemic 
administration of TNF-α siRNA/PPABLG nanocomplexes lead to effective TNF-α knockdown. The 
remarkable anti-inflammatory properties of TNF-α siRNA/PPABLG make it a promising candidate 
for anti-inflammation therapies. 
Figure 11. (A) Schematic illustration of synthesis of the branched modified R9 (B-mR9) CPP and
construction of pDNA and siRNA polyplexes. Positively charged B-mR9 can be complexed with
negatively charged genes through electrostatic interactions. B-mR9 polyplexes were delivered into cells
by means of CPP-mediated permeabilization. The branched structures of B-mR9 were then cleaved by
the reductive conditions of the cytoplasm. Finally, pDNA or siRNA was released into the nucleus or
cytoplasm, respectively. (B) Naked dye and B-mR9/siVEGF polyplexes were intravenously injected
into NCI-H460 tumor-bearing mice and the biodistribution was observed over 48 h. Adapted and
modified from [148], with permission. Copyright: 2017 Elsevier.
Basic amphiphilic ppTG1 and ppTG20 peptides used for pDNA delivery showed membrane-
destabilizing activities that correlated with the peptides’ tendency to predominantly be in an α-helical
conformation [154]. Compared to control peptides, the peptiplexes showed a higher gene transfer
efficiency in the lung, 24 h after tail-vein injection. Similarly, a cationic helical cell-penetrating PVBLG-8,
in combination with anionic random-coiled poly(l-glutamic acid) (PLG) polypeptides was applied
for siRNA delivery [155]. PLG was incorporated in the peptide structure to promote and stabilize
the polypeptide/siRNA nanocomplexes. Due to the high α-helix-dependent membrane penetration
properties of PVBLG-8 and the stability of the complex, these peptiplexes overcame multiple biological
barriers and revealed unique tumor targeting, tumor penetration, and selective internalization features
in xenograft-bearing mice. Likewise, an essential role of helical secondary structure for plasma and
endosomal membrane penetration in promoting cellular uptake and siRNA release was observed
with cationic PPABLG polypeptide (Figure 12) [156]. Accordingly, systemic administration of TNF-α
siRNA/PPABLG nanocomplexes lead to effective TNF-αknockdown. The remarkable anti-inflammatory
properties of TNF-α siRNA/PPABLG make it a promising candidate for anti-inflammation therapies.
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CPP (Tat) and IL-4 receptor targeting (AP1) moieties were used to produce ELP/siRNA peptiplexes 
that delivered siRNA into tumor cells in a receptor-specific fashion [160]. The gene silencing activity 
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with siRNA, showed high gene silencing efficiency [164]. LAH4-L1 was able to promote endosomal
escape of peptiplexes by destabilizing the endosomal membrane when its four histidine residues were
positively charged at low pH.
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Figure 13. Schematic illustration of endosomal escape promoted by histidine-enriched multifunctional
peptide gene vectors. Adapted from [163], with permission. Copyright: 2013 Royal Society of Chemistry.
With regard to in vivo applications, histidylation of various non-viral systems, including polylysine
as an early example, was used to take advantage of the proton sponge effect and facilitate delivery
of genetic payload to the cytosol [115,165–169]. Histidine improved the transfection efficiency
of PEGylated PLL/siRNA nanocomplexes for silencing endogenous vascular endothelial growth
factor (VEGF) expression [169]. A significantly higher tumor growth inhibition was observed in
HepG2-bearing mice injected with histidylated PEG-PLL/siRNA, compared to non-histidylated
counterparts. Similarly, human hypertrophic scar tissue grafts were reduced in size when treated
with nanoplexes of H3K4b, an optimized peptide polymer consisting of a lysine core with four
branches that contain multiple repeats of histidines and lysines, and siRNAs targeting TGF-β1 and
COX-2 [170]. A corresponding HK polymer/siRNA complex was additionally conjugated to an
anti-cancer drug as a novel approach for cancer therapy [171]. Likewise, reducible self-assembling
poly(l-arginine)-poly(l-histidine)-stearoyl polyplexes were used for the co-delivery of microRNA and
doxorubicin in androgen-independent prostate cancer treatment (Figure 14A) [172]. Incorporation of a
non-invasive near-infrared probe, DIR, as an indicator in MiR polyplexes, allowed for the imaging
of MiR biodistribution in tumor-bearing mice (Figure 14B). Moreover, investigation of the excised
organs after 24 h revealed a strong fluorescence associated with the tumor of mice treated with
DIR/MiR polyplexes, whereas tumors of untreated mice and of mice injected with free DIR showed no
fluorescence (Figure 14C,D).
The beneficial properties of arginine, histidine, and stearyl with regard to gene delivery,
i.e., the propensity for membrane penetration, for promoting cellular uptake and endosomal escape,
were combined in SHRss peptides (Figure 15A) [173]. SHRss2/Cy5-siRNA nanocomplexes showed
5.9 times higher mean fluorescence intensity in tumor tissue compared to free Cy5-siRNA, after their
respective intravenous administration (Figure 15B,C). The in vivo luciferase activity was significantly
reduced in tumor xenografts after tail vein injections of SHRss2/Luc-siRNA nanocomplexes, supporting
the nanocomplexes’ ability for gene silencing (Figure 15D).
Bioreducible fluorinated peptide dendrimer (BFPDs)/pDNA polyplexes (Figure 16A) showed
a superior biocompatibility in vivo and a 77-fold higher gene transfection efficiency, compared to
polyetherimide/pDNA complexes (Figure 16B,C) [174].
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arginine)-poly(L-histidine)-stearoyl polyplexes and their intracellular uptake. (B) In vivo imaging of 
DU145 tumor-bearing mice after tail vein injection of DIR and DIR/MiR polyplexes at 2, 6, 12, and 24 
h, respectively. (C) Ex vivo imaging of tumor and organs collected 24 h post-injection. (D) 
Quantification of the ex vivo tumor and organs uptake of DiR and DiR/MiR-PMs by Imaging software 
(Caliper Life Sciences). Reproduced from [172], with permission. Copyright: 2016 Elsevier. 
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arginine)-poly(l-histidine)-stearoyl polyplexes and their intracellular uptake. (B) In vivo imaging of
DU145 tu or-beari ice fter t il ei i jecti f I a IR/ iR polyplexes at 2, 6, 12, and 24 h,
respectively. (C) Ex vivo imaging of tumor and organs collected 24 h post-injection. (D) Quantification
of the ex vivo tumor and organs uptake of DiR and DiR/MiR-PMs by Imaging software (Caliper Life
Sciences). Reproduced from [172], with permission. Copyright: 2016 Elsevier.
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tumor bearing mice after 4 h (blue arrows indicate the location of xenograft tumors). (C) Luciferase 
activity of the tumor tissue lysate after Cy5-siRNA and SHRss2/Cy5-siRNA nanocomplexes 
injections. (D) Luminescent images of tumors before and after SHRss2/NC-siRNA or SHRss2/siLuc 
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Figure 16. (A) Schematic illustrating chemical structure and preparation method of BFPDs 
peptiplexes for intratumoral gene delivery and their transport across the different intracellular 
barriers. Transfection efficacy of (B) pCMV-β-gal and (C) pSC-Luc, in mouse muscles after 
Figure 15. (A) Schematic illustration of self-assembly of cationic disulfide cross-linked SHRss and its
complexation with negatively charged siRNA. (B) In vivo distribution and gene silencing efficiency
of naked Cy5-siRNA and SHRss2/Cy5-siRNA nanocomplexes, after tail vein injection into xenograft
tumor bearing mice after 4 h (blue arrows indicate the location of xenograft tumors). (C) Luciferase
activity of the tumor tissue lysate after Cy5-siRNA and SHRss2/Cy5-siRNA nanocomplexes injections.
(D) Luminescent images of tumors before and after SHRss2/NC-siRNA or SHRss2/siLuc nanocomplex
injections. Reproduced from [173], with permission. Copyright: 2015 American Chemical Society.
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efficacy of (B) pCMV-β-gal and (C) pSC-Luc, in mouse muscles after intramuscular injection of PEI,
BFPD-11, and BPD-11 polyplexes for 4 days. Reproduced from [174], with permission. Copyright: 2016
American Chemical Society.
4. In Vivo Applications of Peptide-Based Nanoassemblies as Probes for Diagnostic Imaging
Rapid and accurate disease diagnosis is of crucial importance for effective therapy and the
prevention of disease progression to incurable stages. Current diagnostic modalities routinely used in
clinical and preclinical studies include computed tomography (CT) [175], magnetic resonance imaging
(MRI) [176], positron emission tomography (PET) [177], ultrasound (US) [178], optical imaging [179],
and photothermal imaging [180]. The choice of diagnostic modality depends on many factors, such as
the underlying pathological condition, the tissue/organ, and the intended application. For example,
optical and photoacoustic imaging are suitable for studying superficial structures, endoscopy is a
powerful tool for examining the walls and internal organs of the gastrointestinal tract and digestive
diseases [181], non-invasive MRI, PET, and CT can be applied for whole-body imaging [182], while
ultrasound is a rapid and low-cost method of examining the body’s internal organs [183].
In addition to the advantage of easy synthesis and extensive options for molecular design,
self-assembling peptide nanostructures are expanding their applicability in diagnostic imaging through
covalent conjugation or physical incorporation of various “imaging” agents [184]. However, developing
sensitive and stable peptide nanomaterials for accurate analysis and sensitive detection of diseases
remains a big challenge. We present here only the recent advances in the development of peptide-based
nanoassemblies and their functionalities for in vivo diagnostic imaging, and refer to their potential in
clinical applications.
4.1. Micelle Nanoprobes
While peptide amphiphile micelles are currently being developed for a wide range of diagnostic
applications, their rapid in vivo degradation through proteolysis limit their clinical applications [185].
In this context, co-assembly of peptide amphiphiles and polymers into micelles is an effective way
to enhance stability, as was shown for gadolinium-decorated pluronic F127 and peptide amphiphile
(pal-AAAAHHHD) hybrid micelles [186]. Gadolinium(III) chelated by the poly(ethylene-oxide)
(PEO)/peptide shell of the hybrid micelles circulated much longer than clinically established Gd-DTPA.
These findings strongly back the concept of tailoring hybrid micelles to specific requirements, through
simple variation of their composition rather than through synthesis of new materials.
In addition, as PEGylation improves water solubility, stability, and circulation time [125], micelles
self-assembled from amphiphilic PEG-polypeptide hybrid triblock copolymers (PEG-PLL-PLLeu)
that contained a near-infrared (NIR) fluorescence dye (indocyanine green; ICG) were used for NIR
fluorescence imaging (Figure 17) [187]. Optical imaging using NIR light represents a new imaging
modality allowing for visualizing deep-tissue structures. In vivo experiments demonstrated exact
tumor localization and prolonged circulation of the NIR micelles.
4.2. Nanofibers Improve the Accumulation of Contrast Agents
The high surface-area to volume ratio of peptide-based nanofibers that allows for the extensive
encapsulation of imaging agents, makes them attractive for diagnostic applications. In addition,
nanofibers based on their size and geometry are prone to being retained in complex tissue environments.
Given appropriate conditions, a peptide comprising an RGD recognition motif for targeting
integrins (which are highly expressed in renal cell carcinoma (RCC)), a cleavage site for matrix
metalloproteinases (MMP)-2/9 (which are typically overexpressed in the tumor microenvironment),
and an NIR moiety (Cy) for signaling, self-assembled to nanofibers in solution (Figure 18) [188].
When injected into mice bearing orthotopic RCC xenografts, the RGD targeted the peptide monomers
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to the tumor where they were cleaved by MMP-2/9 and gradually self-assembled into nanofibers
in situ. Owing to their size and interactions, the nanofiber probes were retained in the tumor
microenvironment, enabling high-performance imaging of the RCC. In addition, lesions below 1 mm
were identified in an ex vivo human tumor-bearing kidney, emphasizing the potential of nanofibers in
clinical image-guided surgery.
Molecules 2020, 25, x FOR PEER REVIEW 21 of 37 
 
intramuscular injection of PEI, BFPD-11, and BPD-11 polyplexes for 4 days. Reproduced from [174], 
with permission. Copyright: 2016 American Chemical Society. 
4. In Vivo Applications of Peptide-Based Nanoassemblies as Probes for Diagnostic Imaging 
Rapid and accurate disease diagnosis is of crucial importance for effective therapy and the 
prevention of disease progression to incurable stages. Current diagnostic modalities routinely used 
in clinical and preclinical studies include computed tomography (CT) [175], magnetic resonance 
imaging (MRI) [176], positron emission tomography (PET) [177], ultrasound (US) [178], optical 
imaging [179], and photothermal imaging [180]. The choice of diagnostic modality depends on many 
factors, such as the underlying pathological condition, the tissue/organ, and the intended application. 
For example, optical and photoacoustic imaging are suitable for studying superficial structures, 
endoscopy is a powerful tool for examining the walls and internal organs of the gastrointestinal tract 
and digestive diseases [181], non-invasive MRI, PET, and CT can be applied for whole-body imaging 
[182], while ultrasound is a rapid and low-cost method of examining the body’s internal organs [183]. 
In addition to the advantage of easy synthesis and extensive options for molecular design, self-
assembling peptide nanostructures are expanding their applicability in diagnostic imaging through 
covalent conjugation or physical incorporation of various “imaging” agents [184]. However, 
developing sensitive and stable peptide nanomaterials for accurate analysis and sensitive detection 
of diseases remains a big challenge. We present here only the recent advances in the development of 
peptide-based nanoassemblies and their functionalities for in vivo diagnostic imaging, and refer to 
their potential in clinical applications. 
4.1. Micelle Nanoprobes 
While peptide amphiphile micelles are currently being developed for a wide range of diagnostic 
applications, their rapid in vivo degradation through proteolysis limit their clinical applications [185]. 
In this context, co-assembly of peptide amphiphiles and polymers into micelles is an effective way to 
enhance stability, as was shown for gadolinium-decorated pluronic F127 and peptide amphiphile 
(pal-AAAAHHHD) hybrid micelles [186]. Gadolinium(III) chelated by the poly(ethylene-oxide) 
(PEO)/peptide shell of the hybrid micelles circulated much longer than clinically established Gd-
DTPA. These findings strongly back the concept of tailoring hybrid micelles to specific requirements, 
through simple variation of their composition rather than through synthesis of new materials. 
In addition, as PEGylation improves water solubility, stability, and circulation time [125], 
micelles self-assembled from amphiphilic PEG-polypeptide hybrid triblock copolymers (PEG-PLL-
PLLe ) that contained a near-i frared (NIR) fluorescence dye (indocyanine gree ; ICG) were used 
for NIR fluorescence imaging (Figure 17) [187]. Optical imaging using NIR light represents a new 
imaging modality allowing for visualizing deep-tissue structures. In vivo experiments dem nstrated 
exact tu or localization and prolonged circulation of the NIR micelles. 
 
Figure 17. (A) Chemical structure of the PEG-PLL-PLLeu copolymer, formation of the micelle and the 
release behavior of ICG in cells. (B) Survival of H460 cells without and with 808 nm laser irradiation 
(green, calcein AM; red, propidium iodide). (C) Fluorescence images of organs and tumors in NCI-
Figure 17. (A) Chemical structure of the PEG-PLL-PLLeu copolymer, formation of the micelle and the
release behavior of ICG in cells. (B) Survival of H460 cells without and with 808 nm laser irradiation
(green, calcein AM; red, propidium iodide). (C) Fluorescence images of organs and tumors in NCI-H460
tumor-bearing mice after the injection of ICG-labeled PEG-PLL-PLLeu micelles. Adapted from [187],
with permission. Copyright: 2013 American Chemical Society.
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Figure 18. (A) Modular molecular design of the NIR peptide and the self-assembly of the peptide after
cleavage by MMP-2/9. (B) NIR fluorescence image of tumor-bearing human kidney tissue after ex vivo
perfusion for 2 h. Adapted and modified from [188], with permission. Copyright: 2020 American
Chemical Society.
t er IR dye-labeled peptide (P18-PLGVRGRGD) forming anofibers at tumor sites was used
in photoacoustic imaging (PA) [181,189–191]. This peptide com rised an RGD for tumor targeting and
a sequence (PLGVRG) that was cleaved by gelatinase overexpressed in the tumor microenvironment.
Subsequently, fibrous nanostructures self-assembled, which exhibited an nhanced PA signal and a
prolo ged retention time in tumors.
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A study involving a mitochondria targeting tripeptide, Mito-FF, and its mirror pair Mito-ff revealed
that either enantiomer self-assembled narrow fibers of 10 nm width, while heterochiral assembly
(Mito-FF/ff) produced superfibrils of around 100 nm in diameter, and 0.5–1 µm in length, due to strong
backbone interactions between opposite enantiomers and strong interfiber interactions. Superfibril
formation through co-assembly of racemic mixtures (Mito-Rac) was observed inside mitochondria,
resulting in disrupted mitochondria both in vitro and in tumor xenografts [192]. In addition, SPECT/CT
(single-photon emission computed tomography combined with computed tomography) imaging
revealed an efficient tumor localization of peritumorally applied 123I-radiolabeled Mito-FY and Mito-fy
peptides. This study unveiled the potential of a chirality in tuning supramolecular peptide assembly
for biological applications.
Furthermore, a series of nanofibers based on self-assembling peptide analogues was tested for
tumoral uptake and biodistribution in vivo, in real-time, through PET/CT imaging (Figure 19) [78].
All peptide precursors were PEGylated to reduce nanofiber removal through the reticuloendothelial
system and had the ability to structurally evolve into an interfibril network for prolonging the retention
on site. PET/CT imaging employing 89Zr-labeled GSH-NFP, the analogue with the most effective
features in terms of tumoral delivery and drug retention, showed that the nanofibers accumulated at
the tumor periphery and in the main organs, and were cleared after 7 days. Notably, based on the
multifunctionality of the nanofibers they did not require a targeting ligand to achieve tumor-specific
biodistribution, which expands their applications to cancers that lack cognate receptors.
Peptides that change conformation in response to external stimuli are of particular interest in
diagnosis. For example, peptides that respond to the acidic pH typical for tumor microenvironments
(pH 5.5–6.0) might prove useful in cancer detection. For example, a pH-responsive peptide, BP-FFVLK-
PEG-His6, which at pH 7.4 self-assembled nanoparticles and transformed to form nanofibers at pH 6.5,
was used for the fluorescence imaging [193]. When the nanoparticles were injected into tumor-bearing
mice, the acidic tumor microenvironment triggered a change of hydrophobic/hydrophilic balance
in BP-FFVLK-PEG-His6, leading to the formation of nest-like nanofibrillar clusters that covered the
tumor region and had retention times up to 96 h. Similarly, pH-trigged self-assembled peptide
conjugates consisting of a hydrophilic peptide (STP: SKDEEWHKNNFPLSP) and a hydrophobic
tetraphenylethylene molecule, were designed for fluorescence imaging [194]. The morphology of
the self-assembled conjugates that changed from nanoparticles, resulted in the accumulation of more
signal molecules at the tumor site. Similarly, the transformation of Ppdf-Gd-based nanoparticles to
nanotubes triggered by MMP-2-cleavage, effectively improved the accumulation and retention of a
GD-based contrast agent (Gd-DOTA) in the tumor [195].
4.3. Nanotubes Offer More Opportunity for Functionalization
Peptide-based nanotubes are promising materials for diagnosis because their surface properties
including charge and hydrophobicity/hydrophilicity can be easily modulated, expanding their
versatility for encapsulating imaging agents or other bioactive compounds [95]. A prominent family of
nanotubes are self-assembling cyclic peptide nanotubes (CPNTs). Due to the cyclic nature of the peptide
building blocks, nanotubes offer several opportunities for functionalization. Multiple modifications on
the periphery [196,197] and also on the interior of CPNTs were reported [198]. More recently, pH and
redox responsive CPNTs were developed [199]. Nanotubes obtained through π-stacking of a cyclic
peptide (cyclo[Gln-(d-Leu-Trp)4-d-Leu], CP) formed artificial channels in membranes, for delivery of
anticancer drugs in liposomes and cancer cells [200]. Even though CPs are known for their antibacterial,
antiviral, and anticancer effects in vitro, in vivo applications are rarely investigated, probably because
CPs non-selectively bind to hydrophobic domains, i.e., target all cell membranes and, thus, are toxic.
In vivo imaging using 125I-labelled CP directly injected into tumors revealed that the radioactivity
was localized to the tumor tissues, with negligible translocation to other tissues. However, no direct
evidence of nanotubes associated with the cancer cells or channel-mediated entry of compounds,
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was provided. For in vivo applications, CPNT development still met many challenges, including
reducing their toxicity and improving specificity.
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with permission. Copyright: 2018 John Wiley & Sons.
4.4. Nanoparticles for Improved Signaling
Peptide NPs are rapidly taking root as nanoprobes for in vivo imaging. For example,
NIR fluorescent peptide nanoparticles (RGD-f-PNPs) were suited for theranostic applications
(Figure 20) [201]. These NPs formed by co-assembly of cyclic octa-peptide cyclo-[(d-Ala-l-Glu-D-Ala-l-
Trp)2-] with Zn2+ ions and signaling is provided by the intrinsic optical properties of the peptide
rather than by integrating fluorophores or quantum dots. Targeting to esophageal cancer (EC) cells
and tumor tissues in corresponding nude mice was achieved by post-assembly conjugating RGD to
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the NPs. In addition, RGD-f-PNPs were loaded with epi-drugs through π-π stacking and electrostatic
interactions. Drug delivery to tumor sites and the therapeutic responses could be monitored in
tumor-bearing nude mice injected with RGD-f-PNPs/EPI through near-infrared fluorescence imaging.Molecules 2020, 25, x FOR PEER REVIEW 25 of 37 
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Self-assembly of cy5.5-modifed poly-L-lysine (PLLs-g-Cy5.5) and PAA decorated Fe3O4 magnetic
nanoparticles (MNPs@PAA) through electrostatic interactions, in the presence of crosslinker,
produced NPs for NIR fluorescence and magnetic resonance imaging (MRI) (Figure 21) [202].
The trypsin-responsive nanoparticles selectively disintegrated upon hydrolysis of PLL by trypsin,
resulting in an 18-fold amplification of the NIR fluorescence and the enhancement of the MRI signal.
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In vivo studies showed that the probes could be used to map malignant tumors overexpressing trypsin
via NIR fluorescence and MR dual imaging.
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e ti e- ase nano aterials for diagnostic ap lications. However, the majority of studies still stay at
the cellular level, and the in vivo application of peptide-based nanoassemblies remains challenging.
Above, we presented some in vivo exa ples that provide cues on epti e designs and co-assembly with
other modules that hold the key to successful imaging. More efforts should focus on the development
of multimodality to enhance the in vivo imaging sensitivity and accuracy. Although peptide-based
nanoassemblies still have a way to go for clinical diagnosis, recent developme ts in preclinical studies
have definitely moved them closer to becoming a reality in the near future.
5. Conclusions
We presented peptide-based nanomaterials (PBNs) and their uses mainly for diagnostic imaging
and gene delivery purposes. We focused on peptides because they have p operties that make
them particularl s ited for these applications: (1) as major structural elemen s in all living
systems, they are inherently bio ompatible, which i vital for in vivo applicatio s, (2) they can
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take on multiple bio-functional roles via different compositions of residues or ensuing conformations,
side chain modifications, and conjugates that can be exploited for developing versatile multifunctional
nanoassemblies, and (3) can serve as recognition and targeting moieties to mediate binding to specific
disease-related markers, which is crucial for diagnostic imaging as well as for targeted gene therapy.
With regard to clinical applications of PBNs, we are aware of only a few that were successfully
used for diagnosis in humans [204], while peptide-mediated gene delivery systems are still in their
infancy. For example, 124I-cRGDY-PEG-C dots were used as a probe in hybrid PET-optical imaging for
lesion detection, cancer staging, and treatment [205]. Evidently, the lack of advanced peptide-mediated
gene delivery systems in clinics highlight the urgency of advancing this class of nanostructures.
Considering that not only peptidic but also lipidic-, polymeric, or inorganic-components are
incorporated in the majority of PBNs structures, many issues concerning toxicity and thermodynamic
stability can be attributed to the non-peptidic part. Therefore, tailoring PBNs for specific clinical
applications remains a major challenge. One possible solution to sidestep concerns related to
non-peptidic components is to develop nanomaterials exclusively based on peptides.
Several parameters should be taken into account when developing future nanoformulations for
safe and effective imaging and targeted gene delivery, or even the combination thereof. First and
foremost, PBNs should be target-specific, sensitive, and should have long-lasting in vivo stability,
while avoiding side effects. For successful gene delivery, PBNs should be efficiently internalized and
then overcome various intracellular barriers, such as the nuclear membrane in the case of gene delivery.
Thus, a better understanding of the fate of PBNs inside cells and their interaction with intracellular
transport mechanisms is required.
Synthesis of such advanced PBNs would require multiple steps in the laboratory, which ultimately
result in high manufacturing costs. Molecular self-assembly, on the other hand, allows for developing
a variety of thermodynamically stable, defined shapes, and functions, at a quicker rate and a cheaper
cost than chemical synthesis. Combining the advantages of self-assembly with the beneficial properties
of peptides is expected to pave the way for future human clinical applications of self-assembled PBNs
in diagnosis and gene therapy.
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